Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patient
Open Access
- 7 May 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 13 (1), 1-7
- https://doi.org/10.1186/s12967-015-0494-0
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosisHuman Molecular Genetics, 2013
- Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyThe Lancet, 2008
- Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-termIn vitroCulture and Do Not Exhibit Telomere Maintenance MechanismsCancer Research, 2007
- Cotransplantation of ex vivo–expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantationBlood, 2007
- Nephropathic Cystinosis in Adults: Natural History and Effects of Oral Cysteamine TherapyAnnals of Internal Medicine, 2007
- Long-term follow-up of well-treated nephropathic cystinosis patientsThe Journal of Pediatrics, 2004
- Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential.2003
- The ZO-1–associated Y-box factor ZONAB regulates epithelial cell proliferation and cell densityThe Journal of cell biology, 2003
- Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in CystinosisMolecular and Cellular Biology, 2002
- Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method.1974